Uveitis patients treated with steroids and immunosuppressants more likely to develop cataract
Patients of uveitis treated with steroids and immunosuppressants more likely to develop cataracts suggests a new study published in the American Journal of Ophthalmology.
A study was done to evaluate the rate of, risk factors for, and outcomes of cataract surgery in patients with intermediate, posterior, and panuveitides treated with systemic corticosteroids and immunosuppression.
Cohort study of participants from a Randomized Clinical Trial. Multicenter clinical trial with extended follow-up. Participants: Cohort of participants assigned to systemic therapy in the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study. Study population: 125 phakic eyes of 74 patients with intermediate, posterior or panuveitides treated with systemic therapy. Main outcome measures: Cataract surgery and visual acuity after cataract surgery.
Results
The cumulative incidence of cataract surgery was 43% at 7-years of follow-up, and the risk did not plateau. Risk factors for cataract surgery included age >50 years (hazard ratio [HR] 2.86; 95% CI 1.52, 5.42; P=0.001), topical corticosteroid use (time-updated HR 3.13; 95% CI 1.42, 6.94; P=0.005), glaucoma medication use (HR 2.75; 95% CI 1.38, 5.47; P=0.004), and possibly history of anterior chamber inflammation (HR 1.90; 95% CI 0.95, 3.84; P=0.07). Median gain in acuity and median best corrected visual acuity 1-year after cataract surgery were 4.8 lines and 20/25, respectively, among 42 eyes undergoing cataract surgery with 1-year follow-up data.
Among patients with intermediate, posterior and panuveitides, treated with oral corticosteroids and immunosuppression, there is a substantial long-term risk of cataract surgery. Visual acuity outcomes after cataract surgery are generally good.
Reference:
Douglas A. Jabs, Elizabeth A. Sugar, Alyce E. Burke, Richard J. Stawell, Janet T. Holbrook. Cataract surgery in patients with uveitis treated with systemic therapy in the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study: risk factors and outcomes. the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group11
Published:July 03, 2023DOI:
https://doi.org/10.1016/j.ajo.2023.06.023
Keywords:
Patient, uveitis, treated, steroids, immunosuppressants, more, likely, develop, cataract, American Journal of Ophthalmology, Douglas A. Jabs, Elizabeth A. Sugar, Alyce E. Burke, Richard J. Stawell, Janet T. Holbrook
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.